GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » Shiller PE Ratio

Regeneron Pharmaceuticals (WBO:REGN) Shiller PE Ratio : 33.09 (As of Apr. 29, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals Shiller PE Ratio?

As of today (2024-04-29), Regeneron Pharmaceuticals's current share price is €827.00. Regeneron Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was €24.99. Regeneron Pharmaceuticals's Shiller PE Ratio for today is 33.09.

The historical rank and industry rank for Regeneron Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

WBO:REGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 26.26   Med: 68.29   Max: 4276.4
Current: 32.24

During the past years, Regeneron Pharmaceuticals's highest Shiller PE Ratio was 4276.40. The lowest was 26.26. And the median was 68.29.

WBO:REGN's Shiller PE Ratio is ranked better than
53.06% of 147 companies
in the Biotechnology industry
Industry Median: 34.81 vs WBO:REGN: 32.24

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was €9.344. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €24.99 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regeneron Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Regeneron Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Shiller PE Ratio Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.39 44.17 32.61 30.55 32.06

Regeneron Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.55 33.38 28.03 30.96 32.06

Competitive Comparison of Regeneron Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Shiller PE Ratio falls into.



Regeneron Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regeneron Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=827.00/24.99
=33.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=9.344/129.4194*129.4194
=9.344

Current CPI (Dec. 2023) = 129.4194.

Regeneron Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.441 99.695 0.572
201406 0.626 100.560 0.806
201409 0.566 100.428 0.729
201412 0.779 99.070 1.018
201503 0.610 99.621 0.792
201506 1.506 100.684 1.936
201509 1.622 100.392 2.091
201512 1.230 99.792 1.595
201603 1.428 100.470 1.839
201606 1.504 101.688 1.914
201609 2.023 101.861 2.570
201612 2.076 101.863 2.638
201703 2.020 102.862 2.542
201706 2.973 103.349 3.723
201709 2.785 104.136 3.461
201712 1.267 104.011 1.577
201803 3.374 105.290 4.147
201806 4.126 106.317 5.023
201809 4.431 106.507 5.384
201812 6.285 105.998 7.674
201903 3.531 107.251 4.261
201906 1.487 108.070 1.781
201909 5.321 108.329 6.357
201912 6.237 108.420 7.445
202003 4.914 108.902 5.840
202006 6.758 108.767 8.041
202009 6.274 109.815 7.394
202012 8.417 109.897 9.912
202103 8.476 111.754 9.816
202106 23.215 114.631 26.210
202109 12.181 115.734 13.621
202112 17.426 117.630 19.173
202203 7.818 121.301 8.341
202206 7.067 125.017 7.316
202209 11.777 125.227 12.171
202212 9.912 125.222 10.244
202303 6.697 127.348 6.806
202306 7.846 128.729 7.888
202309 8.330 129.860 8.302
202312 9.344 129.419 9.344

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regeneron Pharmaceuticals  (WBO:REGN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Regeneron Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals (WBO:REGN) Business Description

Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).